Fundraising FoxARCH Venture Partners — 2018 Investments
13 investments dated 2018 · listed companies and verified rows first · show all
Beam Therapeutics develops gene-editing medicines, particularly base editors and precision genome editing technologies, to create lifelong cures for patients with serious genetic diseases.
BiotechDeep TechMedical DevicesCambridge, US
David R. Liu(Founder)inJ. Keith Joung(Founder)inFeng Zhang(Founder)David R. Liu, Ph.D.(Founder and Inventor)J. Keith Joung, M.D., Ph.D.(Founder and Inventor)Feng Zhang, Ph.D.(Founder and Inventor)
Board seatRobert NelsenKristina Burow· per SEC Form D
Co-investorsDreamers VCEight Roads VenturesF-Prime CapitalForesite CapitalGV (Google Ventures)HongShan Capital Group+2 more
Gossamer Bio is a clinical-stage biopharmaceutical company developing seralutinib, an investigational drug candidate for treating pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.
BiotechDigital HealthMedical DevicesSan Diego, US
Faheem Hasnain(Executive Officer, Director)inChristian Waage(Executive Officer)inSheila Gujrathi, MD(Founder)inBryan Giraudo(Executive Officer)Laura Carter, Ph.D.(Executive Officer)Robert Smith(Executive Officer)
Board seatKristina BurowRobert Nelsen· per SEC Form D
Co-investorsBay City CapitalEcoR1 CapitalFoothill VenturesNew Enterprise Associates (NEA)Pivotal Life SciencesSamsara BioCapital+3 more
GRAIL develops the Galleri blood test for multi-cancer early detection using next-generation sequencing and machine learning to screen for multiple deadly cancer types before symptoms appear.
AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesMenlo Park, US
Jeffrey T. Huber(Director)Joshua Ofman, MD, MSHS(Chief Executive Officer)inAaron Freidin(Executive Officer)inRobert Ragusa(Executive Officer, Director)Jennifer Cook(Executive Officer, Director)inRichard Klausner(Director)
Board seatRobert Nelsen· per SEC Form D
Co-investorsAmino CapitalBezos ExpeditionsBluebird VenturesDecheng CapitalDentsu VenturesFelicis Ventures+13 more
-2.png)
Vir Biotechnology develops treatments for infectious diseases and oncology, leveraging immunology-focused scientific capabilities.
AI & Machine LearningBiotechDigital HealthMedical DevicesSan Francisco, US
Marianne De Backer(CEO)inHerbert Virgin(Executive Officer)Howard Horn(Executive Officer)inAlex Bangs(Executive Officer)inMarianne De Backer, M.Sc., Ph.D., MBA(President, Chief Executive Officer and Director)
BoardGeorge Scangos(Executive Officer, Director)
Board seatRobert NelsenKristina BurowVicki Sato· per SEC Form D
Co-investorsAlta PartnersGV (Google Ventures)SoftBank Vision Fund8VCALTITUDE LIFE SCIENCE VENTURESDCVC (Data Collective)+1 more
Sana is a biotech company developing engineered cell medicines, including gene therapies for gene modification and delivery, cell replacement therapies using stem cell biology, and manufacturing solutions to improve patient access to these treatments.
BiotechHealthtechMedical DevicesSeattle, US
Richard Mulligan(Director)inHans Bishop(Founder)Steve Harr(Founder)James J. MacDonald(Executive Officer)Nathan Hardy(Executive Officer)
.jpg?itok=YnNGtnt9)
BoardGeoffrey von Maltzahn(Director)in
Board seatRobert Nelsen· per SEC Form D
Co-investorsAmerican Family VenturesCatalytic Impact FoundationF-Prime CapitalFlagship PioneeringGV (Google Ventures)Innovating Capital+8 more
Hong Kong-listed (2137.HK) biotech founded in 2018 developing infectious disease therapies, led by hepatitis B functional-cure programs.
Co-investors6 Dimensions CapitalBlue Pool CapitalBoyu CapitalSequoia Capital
Hong Kong-listed (HKEX: 2616) Chinese biopharmaceutical company developing oncology, immunology and inflammation therapies.
Co-investors6 Dimensions CapitalBoyu CapitalGICHillhouse CapitalWuXi Healthcare Ventures
Shanghai-based, HKEX-listed drug developer commercializing dorzagliatin, the first approved glucokinase activator for type 2 diabetes.
Li Chen(Founder)
Co-investorsF-Prime CapitalVenrock6 Dimensions CapitalAlly Bridge GroupBlue Pool CapitalEight Roads Ventures+2 more
KSQ Therapeutics develops eTIL therapies—engineered tumor-infiltrating lymphocyte treatments for solid tumors—using its proprietary CRISPRomics platform to identify and target novel therapeutic candidates through genome-wide CRISPR/Cas9 functional genomic screens.
AI & Machine LearningBiotechMedical DevicesCambridge, US
Tim Wang(Cofounder)JOHN TRZUPEK, PH.D.(TREASURER, SECRETARY & CHIEF FINANCIAL OFFICER)DAVID P. MEEKER, M.D.(PRESIDENT AND CHIEF EXECUTIVE OFFICER)inFRANK STEGMEIER, PH.D.(CHIEF SCIENTIFIC OFFICER)Qasim Rizvi(Chief Executive Officer)inJAMES GILBERT(Director)
Co-investorsAlpha Wave GlobalFlagship PioneeringLAVLG Technology VenturesLilly Asia VenturesBaillie Gifford+3 more
Nebula is a cloud gaming service that lets users stream over 1,000 games instantly on Windows, MacOS, and Android without downloads or installations.
Cloud ComputingConsumerGamingMountain View, US
Gordon Stitt(Executive Officer, Director)Devin Carlen(Director)Chris C. Kemp(Executive Officer, Director)
BoardLouis Toth(Director)inMark Leslie(Director)Peter Bell(Director)
Co-investorsAlpha Startups Pre-AcceleratorComcast VenturesF-Prime CapitalFenbushi CapitalHemi Ventures, LlcHighland Capital Partners+5 more
Nebula Genomics offers whole genome sequencing, providing consumers with health, trait, ancestry, and oral microbiome reports based on 100% of their DNA.
BiotechConsumerDigital Health
George Church(Founder)in
Co-investorsF-Prime CapitalHemi Ventures, LlcHikma VenturesWindham Capital PartnersFenbushi CapitalKhosla Ventures+1 more
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.